Intraoperative Cerenkov Imaging for Guiding Breast Cancer Surgery and Assessing Tumor Margins
Annual summary 1 Dec 2011-30 Nov 2012
LELAND STANFORD JUNIOR UNIV CA
Pagination or Media Count:
Breast-conserving surgery is standard treatment for breast cancer. However, to be effective, the surgery must remove all malignant tissue. Currently, a significant fraction of BCS patients require additional re-excision surgery to remove residual cancer. This grant aims to develop a system to assess tumor margins during surgery, with the eventual goal of reducing re-excision surgery. This new technology should provide accurate information about the status of the margins in real-time, and therefore guide decision-making during surgery. The system can help surgeons decide when to stop the excision, and, if any, where to remove additional malignant tissue. It is hypothesized that the proposed approach, based on Cerenkov luminescence imaging, will help visualize malignant tissue directly in the operating room by exploiting the specificity of 18F-labeled fluorodeoxyglucose for malignant tissues.
- Anatomy and Physiology
- Medicine and Medical Research